CD226 and neoplasm: Overall, detailed characterization of the intra-tumor expression of CD226, CD155, TIGIT, CD112, and CD112R can provide critical insights into the tumor immune landscape, supporting patient selection for more effective, tailored immunotherapeutic strategies.